EA202091092A1 - DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLS - Google Patents

DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLS

Info

Publication number
EA202091092A1
EA202091092A1 EA202091092A EA202091092A EA202091092A1 EA 202091092 A1 EA202091092 A1 EA 202091092A1 EA 202091092 A EA202091092 A EA 202091092A EA 202091092 A EA202091092 A EA 202091092A EA 202091092 A1 EA202091092 A1 EA 202091092A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
mobilization
compositions
stem cells
dosed administration
Prior art date
Application number
EA202091092A
Other languages
Russian (ru)
Inventor
Дуайт Морроу
Патрик С. Фелейхи
Энтони Бойтано
Майкл П. Кук
Кевин А. Гонсалвес
Original Assignee
Маджента Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Маджента Терапьютикс, Инк. filed Critical Маджента Терапьютикс, Инк.
Priority claimed from PCT/US2018/064335 external-priority patent/WO2019113375A2/en
Publication of EA202091092A1 publication Critical patent/EA202091092A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к композициям и способам, применимым для мобилизации популяций гемопоэтических стволовых клеток и клеток-предшественников донора, а также для определения того, подходят ли образцы мобилизованных клеток для выделения с целью наращивания ex vivo и/или терапевтического применения. В соответствии с композициями и способами, описанными в настоящем документе, мобилизованные гемопоэтические стволовые клетки и клетки-предшественники могут быть изъяты у донора и введены пациенту для лечения различных ассоциированных со стволовыми клетками нарушений, в том числе включающих в себя болезни кроветворной системы, метаболические нарушения, злокачественные опухоли и аутоиммунные заболевания. Согласно определенным вариантам осуществления композиции и способы, описанные в настоящем документе, приводят к мобилизации популяции CD34dim клеток, которые обладают иммуносупрессирующими эффектами и которые могут снизить частоту возникновения реакции "трансплантат против хозяина".The present invention relates to compositions and methods useful for mobilizing populations of hematopoietic stem cells and donor progenitor cells, as well as for determining whether samples of mobilized cells are suitable for isolation for ex vivo expansion and / or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem cells and progenitor cells can be removed from a donor and administered to a patient for the treatment of various stem cell-associated disorders, including diseases of the hematopoietic system, metabolic disorders, malignant tumors and autoimmune diseases. In certain embodiments, the compositions and methods described herein result in the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft versus host disease.

EA202091092A 2018-11-30 2018-12-06 DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLS EA202091092A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773954P 2018-11-30 2018-11-30
PCT/US2018/064335 WO2019113375A2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Publications (1)

Publication Number Publication Date
EA202091092A1 true EA202091092A1 (en) 2020-10-09

Family

ID=73129245

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091092A EA202091092A1 (en) 2018-11-30 2018-12-06 DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLS

Country Status (1)

Country Link
EA (1) EA202091092A1 (en)

Similar Documents

Publication Publication Date Title
Szabó et al. Licensing by inflammatory cytokines abolishes heterogeneity of immunosuppressive function of mesenchymal stem cell population
Terai et al. Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis
Liang et al. Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives
Shabbir et al. Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair
ES2756336T3 (en) Methods that modulate the immunoregulatory effect of stem cells
Quijada et al. Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells
Ilmer et al. Two sides of the same coin: stem cells in cancer and regenerative medicine
EA201490911A1 (en) METHODS OF TREATMENT OF MALIGNANT TUMORS WITH THE USE OF ORAL COMPOSITIONS OF CYTIDINE ANALOGUES
Ankersmit et al. Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardium
EA200700886A1 (en) CONNECTION OF TIADIAZOLE AND ITS APPLICATION
JP6898706B2 (en) Mesenchymal stem cells to treat liver disease
Liang et al. Conditioned medium from induced pluripotent stem cell-derived mesenchymal stem cells accelerates cutaneous wound healing through enhanced angiogenesis
MX2020005878A (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells.
CL2020003319A1 (en) Chimeric growth factor receptors
Zhang et al. Human-derived normal mesenchymal stem/stromal cells in anticancer therapies
Oliveira et al. A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation
EA202092459A1 (en) INTERLEUKIN 12 HYBRID PROTEINS, COMPOSITIONS AND METHODS OF THERAPEUTIC APPLICATION, WHICH INCLUDE THEM
Tyndall et al. Stem cell transplantation and mesenchymal cells to treat autoimmune diseases
Kim et al. PIN1 suppresses the hepatic differentiation of pulp stem cells via Wnt3a
Deng et al. Up-regulation of CXCR4 in rat umbilical mesenchymal stem cells induced by serum from rat with acute liver failure promotes stem cells migration to injured liver tissue
Geng et al. HGF-modified dental pulp stem cells mitigate the inflammatory and fibrotic responses in paraquat-induced acute respiratory distress syndrome
Eom et al. Mesenchymal stem cell therapy for liver disease: current status and future perspectives
Lai et al. A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis
Chang et al. From Hair to Colon: Hair Follicle-Derived MSCs Alleviate Pyroptosis in DSS-Induced Ulcerative Colitis by Releasing Exosomes in a Paracrine Manner
Alanazi COVID-19 and the role of stem cells